Keywords: Alkermes, Vivitrol, PharmaLink, Nefon, USA, FDA, Orphan status

US FDA approves Alkermes’ Vivitrol to treat opioid-dependent patients and orphan status for PharmaLink’s Nefecon

Article | 13 October 2010

Print This

The US Food and Drug Administration has approved drugmaker Alkermes’ (Nasdaq: ALKS) alcohol dependence drug Vivitrol (naltrexone) for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in